Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 651

1.

Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Kolarcik C, Bowser R.

Mol Diagn Ther. 2006;10(5):281-92. Review.

PMID:
17022691
[PubMed - indexed for MEDLINE]
2.

Biomarkers for amyotrophic lateral sclerosis.

Bowser R, Cudkowicz M, Kaddurah-Daouk R.

Expert Rev Mol Diagn. 2006 May;6(3):387-98. Review.

PMID:
16706741
[PubMed - indexed for MEDLINE]
3.

Protein biomarkers for amyotrophic lateral sclerosis.

Ryberg H, Bowser R.

Expert Rev Proteomics. 2008 Apr;5(2):249-62. doi: 10.1586/14789450.5.2.249. Review.

PMID:
18466055
[PubMed - indexed for MEDLINE]
4.

Identification of potential CSF biomarkers in ALS.

Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, Brown RH, Cudkowicz ME, Newhall K, Peskind E, Marcus S, Ho L.

Neurology. 2006 Apr 25;66(8):1218-22. Epub 2006 Feb 15.

PMID:
16481598
[PubMed - indexed for MEDLINE]
5.

Biochemical markers in CSF of ALS patients.

Süssmuth SD, Brettschneider J, Ludolph AC, Tumani H.

Curr Med Chem. 2008;15(18):1788-801. Review.

PMID:
18691039
[PubMed - indexed for MEDLINE]
6.

Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.

Ekegren T, Hanrieder J, Bergquist J.

J Mass Spectrom. 2008 May;43(5):559-71. doi: 10.1002/jms.1409. Review.

PMID:
18416436
[PubMed - indexed for MEDLINE]
7.

CSF glial markers correlate with survival in amyotrophic lateral sclerosis.

Süssmuth SD, Sperfeld AD, Hinz A, Brettschneider J, Endruhn S, Ludolph AC, Tumani H.

Neurology. 2010 Mar 23;74(12):982-7. doi: 10.1212/WNL.0b013e3181d5dc3b.

PMID:
20308682
[PubMed - indexed for MEDLINE]
8.

TDP-43 in differential diagnosis of motor neuron disorders.

Dickson DW, Josephs KA, Amador-Ortiz C.

Acta Neuropathol. 2007 Jul;114(1):71-9. Epub 2007 Jun 14.

PMID:
17569066
[PubMed - indexed for MEDLINE]
9.

Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.

Gordon PH, Cheng B, Katz IB, Mitsumoto H, Rowland LP.

Neurology. 2009 Jun 2;72(22):1948-52. doi: 10.1212/WNL.0b013e3181a8269b.

PMID:
19487653
[PubMed - indexed for MEDLINE]
10.

Approaching clinical proteomics: current state and future fields of application in fluid proteomics.

Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Müllner S, Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert K, Rothe G, Stockinger H, Tarnok A, Taussig MJ, Thiel A, Thiery J, Ueffing M, Valet G, Vandekerckhove J, Verhuven W, Wagener C, Wagner O, Schmitz G.

Clin Chem Lab Med. 2009;47(6):724-44. doi: 10.1515/CCLM.2009.167. Review.

PMID:
19527139
[PubMed - indexed for MEDLINE]
11.

[Objective markers for upper motor neuron involvement in amyotrophic lateral sclerosis].

Iwata NK.

Brain Nerve. 2007 Oct;59(10):1053-64. Review. Japanese.

PMID:
17969345
[PubMed - indexed for MEDLINE]
12.

Amyotrophic lateral sclerosis--the tools of the trait.

Lederer CW, Santama N.

Biotechnol J. 2007 May;2(5):608-21. Review.

PMID:
17345579
[PubMed - indexed for MEDLINE]
13.

Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Pradat PF, Dib M.

Mol Diagn Ther. 2009;13(2):115-25. doi: 10.2165/01250444-200913020-00005. Review.

PMID:
19537846
[PubMed - indexed for MEDLINE]
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
[PubMed - indexed for MEDLINE]
15.

[Biomarkers for amyotrophic lateral sclerosis].

Tokuda T.

Brain Nerve. 2012 May;64(5):515-23. Review. Japanese.

PMID:
22570065
[PubMed - indexed for MEDLINE]
16.

Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery.

Krüger T, Lautenschläger J, Grosskreutz J, Rhode H.

Proteomics Clin Appl. 2013 Jan;7(1-2):123-35. doi: 10.1002/prca.201200067. Review.

PMID:
23129563
[PubMed - indexed for MEDLINE]
17.
18.

The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.

Amacher DE.

Toxicol Appl Pharmacol. 2010 May 15;245(1):134-42. doi: 10.1016/j.taap.2010.02.011. Epub 2010 Feb 26. Review.

PMID:
20219512
[PubMed - indexed for MEDLINE]
19.

Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic.

von Neuhoff N, Oumeraci T, Wolf T, Kollewe K, Bewerunge P, Neumann B, Brors B, Bufler J, Wurster U, Schlegelberger B, Dengler R, Zapatka M, Petri S.

PLoS One. 2012;7(9):e44401. doi: 10.1371/journal.pone.0044401. Epub 2012 Sep 6.

PMID:
22970211
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up.

Tartaglia MC, Rowe A, Findlater K, Orange JB, Grace G, Strong MJ.

Arch Neurol. 2007 Feb;64(2):232-6.

PMID:
17296839
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk